TORONTO, Jan. 24, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced
today that the company has been selected to present an oral platform
entitled "AMF-1c-120: an antibody specific for misfolded prion protein
expressed on ovarian cancer cells", at the annual meeting of the
American Association for Cancer Research (AACR) in Washington, DC on
April 9, 2013.
The Company will present the results of studies demonstrating the
selective binding of its proprietary antibody, AMF-1c-120, to ovarian
cancer cells, but not normal ovarian cells, as well as the killing of
ovarian cancer cells with an antibody-toxin conjugate. These results
validate the Company's ProMIS™ discovery technology as a valuable
scientific platform enabling the development of novel, targeted
therapeutic antibodies for the treatment of cancer and other diseases.
Dr. Neil Cashman, Amorfix's Chief Scientific Officer said, "It is an
honour to be one of the few participants selected for an oral
presentation at this premier cancer research conference. We look
forward to sharing our exciting results with the scientific community
working to battle this common and terrible disease".
The Company is developing AMF-1c-120 as a new therapeutic for the
treatment of ovarian cancer and is in preclinical animal models of
disease at present. The Company is also developing additional
antibodies for the treatment of other types of cancers with their
unique and proprietary ProMIS™ platform for identifying cancer specific
targets that spare normal cells.
About the ProMIS Discovery Technology and the Company's Prion Protein
Amorfix's proprietary drug discovery technology, ProMIS™, is a computer
based algorithm that predicts Disease Specific Epitopes (DSEs), those
regions of proteins most likely to misfold in diseases. Misfolded
proteins are found in numerous diseased cells, including various
cancers and neurodegenerative diseases. The Company uses this
technology to identify DSEs which are only expressed on tumor cells and
not on normal cells as a way of developing antibodies that only bind to
and kill tumor cells without affecting normal cells. Using this
technology, Amorfix has the potential to create antibody therapeutics
that are more efficacious and have a much better safety profile, with
fewer side effects than current cancer therapeutics.
About Ovarian Cancer
Ovarian cancer is the fifth most common cancer among women, and it
causes more deaths than any other type of female reproductive cancer.
Most deaths from ovarian cancer occur in women age 55 and older.
Ovarian cancer is often not diagnosed until late-stage disease when the
cancer has spread to other organs in the body, which contributes to the
short survival time following diagnosis. Ovarian cancer is typically
treated with surgery and chemotherapy. Chemotherapy is not very
effective as a treatment and is associated with a number of potential
dose-limiting side effects due to its non-specific killing of both
tumour and normal cells.
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS™, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection™ and
AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a human cerebrospinal fluid (CSF) screening
test for Alzheimer's disease (AD) and mild cognitive impairment (MCI),
and an ultrasensitive method for detecting the hallmark of AD,
aggregated beta-Amyloid, in brain tissue, CSF and blood from animal
models of AD. For more information about Amorfix, visit www.amorfix.com
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
SOURCE: Amorfix Life Sciences Ltd.
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899